|
|
 |
|
| •
|
Markers
of fibrinolysis and CVD risk
|
| •
|
Patients
with HIV and fat redistribution were compared to age and BMI-matched
subjects
|
| •
|
Those
with fasting insulin or impaired glucose tolerance received
metformin
|
| •
|
500
mg BID for 12 weeks |
• Another study by Hadigan and colleagues has examined the impact
of metformin therapy on plasminogen activator inhibitor-1 and tissue-type
plasminogen activator antigen levels in HIV-infected patients with
fat redistribution and insulin resistance.1 Both of these are markers
of fibrinolysis and increased cardiovascular disease risk.
• In this study, 86 patients were compared to 258 age- and BMI-matched
subjects from the Framingham Offspring study.
• An additional 25 patients with fasting insulin above 15 _U/mL
or impaired glucose tolerance, but who did not have diabetes, were
enrolled in a placebo-controlled trial of metformin at 500 mg twice
daily for 12 weeks.
Reference:
1. Hadigan C, Meigs JB, Rabe J et al. Increased PAI-1 and tPA antigen
levels are reduced with metformin therapy in HIV-infected patients
with fat redistribution and insulin resistance. J Clin Endocrinol
Metab. 2001;86:939-43.
|
|
|
|
